Tofacitinib inhibits granulocyte–macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils

Abstract

BackgroundGranulocyte–macrophage colony-stimulating factor (GM-CSF) has emerged as a crucial cytokine that activates myeloid cells to initiate tissue inflammation. However, the molecular actions of GM-CSF against innate immunity are still poorly characterized. Here, we investigated the in vitro effects of GM-CSF on the activation of human myeloid lineages, neutrophils, and the underlying intracellular signaling mechanism, including inflammasome activation.MethodsHuman neutrophils were stimulated with GM-CSF in the presence or absence of tofacitinib. The cellular supernatants were analyzed for interleukin-1 beta (IL-1β) and caspase-1 by enzyme-linked immunosorbent assay (ELISA) methods. Pro-IL-1β mRNA expressions in human neutrophils were analyzed by real-time polymerase chain reaction. Protein phosphorylation of neutrophils was assessed by Western blot using phospho-specific antibodies.ResultsStimulation with GM-CSF alone, but not tumor necrosis factor-alpha, was shown to increase the release of IL-1β and cleaved caspase-1 (p20) from human neutrophils. Tofacitinib, which inhibits GM-CSF–induced Janus kinase 2 (Jak2)-mediated signal transduction, completely abrogated GM-CSF–induced IL-1β and caspase-1 (p20) secretion from neutrophils. GM-CSF stimulation also induced pro-IL-1β mRNA expression in neutrophils and induced NLR family pyrin domain-containing 3 (NLRP3) protein expression. Although tofacitinib pretreatment marginally inhibited GM-CSF–induced pro-IL-1β mRNA expression, tofacitinib completely abrogated NLRP3 protein expression in neutrophils.ConclusionsThese results indicate that GM-CSF signaling induces NLRP3 expression and subsequent IL-1β production by affecting neutrophils, which may cause the activation of innate immunity. Therefore, GM-CSF is a key regulator of the NLRP3 inflammasome and IL-1β production by activating innate immune cells. This process can be blocked by tofacitinib, which interferes with JAK/STAT signaling pathways.Electronic supplementary materialThe online version of this article (10.1186/s13075-018-1685-x) contains supplementary material, which is available to authorized users.

The hidden role of NLRP3 inflammasome in obesity‐related COVID‐19 exacerbations: Lessons for drug repurposing

“…Experimental evidence for key roles of the JAK and BTK cascades in modulating expression of the NLRP3 inflammasome and diabesity pathogenesis has been published (Collotta et al, 2020;Furuya et al, 2018;Purvis et al, 2020).…”

“…A study on baricitinib has already been concluded with interesting results (NCT04358614), and others are recruiting patients for both the treatments (baricitinib: NCT04320277 and NCT04390464; acalabrutinib: NCT04346199 and NCT04380688). Experimental evidence for key roles of the JAK and BTK cascades in modulating expression of the NLRP3 inflammasome and diabesity pathogenesis has been published (Collotta et al, 2020; Furuya et al, 2018; Purvis et al, 2020).…”

Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China

“…The cytokine storm activated by neutrophils and macrophages is strongly implicated in AOSD pathogenesis 1. Tofacitibib inhibits the effect of IL-6, IL-10, IFN-γ, INF-α and granulocyte macrophage-colony stimulating factor (GM-CSF), thus suppressing neutrophils NOD-like receptor family pyrin domain-containing 3 (NLRP3) activation and IL-1β production 9. Tofacitinib also suppresses macrophage activation and function 10.…”

JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells

“…These results suggest that JAKi inhibited the GM-CSF-induced inflammasome activation process, such as caspase-1 activation and subsequent IL-1β production, without affecting the inflammasome priming process [23]. Since JAK2 is associated with signaling downstream of GM-CSF [24], inhibition of JAK2 may lead to the impaired the GM-CSF-mediated autoinflammation pathway in innate immune cells [25]. We observed similarities between baricitinib and upadacitinib in the inhibitory effects on the GM-CSF-induced JAK2/STAT5 phosphorylation in innate immune cells.…”